MRKR
Marker Therapeutics Inc
Clinical-stage immuno-oncology company developing T cell-based immunotherapies
CUSIP: 57055L206HealthcareUS1 holder
Recent Activity
2023Q3
1 sell
-25.0K shares(-62.5%)
-25.0K shares(-62.5%)
Loading more activity...
Marker Therapeutics Inc
Clinical-stage immuno-oncology company developing T cell-based immunotherapies